Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE)

Jérémie Rouger-Gaudichon 1, Yves Bertrand 2, Nicolas Boissel 3, Benoit Brethon 4, Stéphane Ducassou 5, Virginie Gandemer 6, Carine Halfon-Domenech 7, Thierry Leblanc 8, Guy Leverger 7, Gérard Michel 8, Arnaud Petit 7, Anne-France Ray-Lunven 4, Pierre-Simon Rohrlich 9, Pascale Schneider 10, Nicolas Sirvent 11, Marion Strullu 4, André Baruchel 4, for the Leukemia Committee of the SFCE

Received 31 January 2021
Accepted 21 February 2021
Available online: 11 March 2021

1. Unité d’hémato-oncologie pédiatrique, CHU Caen, avenue de la Côte de Nacre, 14033 Caen cédex 9, France
2. Institut d’hématologie pédiatrique, CHU Lyon, 3, quai des Célestins, 69002 Lyon, France
3. Université de Paris, unité adolescents et jeunes adultes, hôpital Saint-Louis (APHP), 1, avenue Claude-Vellefaux, 75010 Paris, France
4. Université de Paris, service d’hématologie-immunologie pédiatrique, hôpital universitaire Robert-Debré (APHP), boulevard Séruer, 75019 Paris, France
5. Groupe hospitalier Pellegrin, unité d’hématologie-oncologie pédiatrique, place Amélie-Raba-Léon, 33000 Bordeaux, France
6. Service d’hématologie-oncologie pédiatrique, CHU Rennes, 16, boulevard de Bulgarie, 35200 Rennes, France
7. Hôpital Armand-Trousseau (APHP) et Sorbonne Université, service d’hématologie-oncologie pédiatrique, 26, avenue du Docteur-Arnold-Netter, 75571 Paris cédex 12, France
8. CHU la Timone, service d’hématologie pédiatrique, 264, rue Saint-Pierre, 13385 Marseille cédex 5, France
9. CHU l’Archet, service d’hématologie-oncologie pédiatrique, 151, route de Saint-Antoine, 06200 Nice, France
10. CHU Charles-Nicolle, service d’hématologie pédiatrique, 37, boulevard Gambetta, 76038 Rouen, France
11. CHU Arnaud-de-Villeneuve, service d’hématologie et oncologie pédiatrique, 191, avenue du Doyen-Graud, 14295 Montpellier cédex 5, France

Correspondence:
André Baruchel, Université de Paris, service d’hématologie-immunologie pédiatrique, hôpital universitaire Robert-Debré (APHP), boulevard Séruer, 75019 Paris, France.
andre.baruchel@aphp.fr

COVID19 et leucémies lymphoblastiques aiguës de l’enfant et de l’adolescent: recommandations actualisées (Version 2) du Comité « Leucémies » de la Société Française de lutte contre les Cancers et leucémies de l’Enfant et l’adolescent (SFCE)
Keywords
SARS-CoV-2
COVID 19
Acute lymphoblastic leukemia
Children
Adolescents

Summary
Since the emergence of the SARS-CoV-2 infection, many recommendations have been made. However, the very specific nature of acute lymphoblastic leukaemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against Cancers and leukaemias in children and adolescents (SFCE) to propose more specific recommendations. Here is the second version of these recommendations updated according to the evolution of knowledge on COVID-19.

Preamble and general recommendations
Preamble
The situation of the current COVID-19 pandemic is continuously evolving. We thus have taken the more recent knowledge into account to update the previous recommendations from the Leukemia Committee of the Société Française de lutte contre les Cancers et leucémies de l’Enfant et de l’Adolescent (SFCE) [1].

Despite an increasing number of publications concerning severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pediatric oncology and hematology, data in children with cancer are still limited (table 1). Published recommendations most often rely on an expert-opinion basis [2,3]. While some early studies in adults with cancers suggested that the risk of severe COVID-19 is higher in this population [4,5], more recent data indicate that patients with cancer may not be at greater risk than others when matched for comorbidities [6,7]. However, mortality appears to be higher in adults with haematological malignancies [8,9].

In pediatric oncology, most reports have been limited to cases or small sample populations [10-17] while larger clinical studies have recently been published and/or are still ongoing [18-20]. These reports suggest that COVID-19 is generally asymptomatic, mild or moderate in children receiving anti-cancer therapy. Thus children with cancer appear to have a similar risk of developing severe COVID-19 compare to those in their healthy counterparts. However, some severe cases have been described, mostly in highly immunocompromised children and/or with severe oncologic conditions [14,15,18,21,22]. Since April 2020, a real-time prospective survey has been set up among the 30 SFCE centers. On 17th of December 2020, 127 cases of COVID-19 have been reported, most of them being enrolled in the PEDONCOVID study (NCT04433871). Eight patients required hospitalization in intensive care unit (ICU) and one patient with relapsed acute lymphoblastic leukemia (ALL) died from ARDS with multi-organ failure. Thus, SARS-CoV-2 infection can be severe in some children with cancer and/or HSCT, as suggested by the first reports from the SFCE [21,23] or available through the St-Jude Research Hospital Registry (to which the SFCE is participating) [24].

Fortunately, SARS-CoV-2 infection appears nevertheless to be mild in most children with cancer/ALL [20,23,25,26]. Thus, the main threat to the vast majority of children with ALL still remains the ALL itself. Long-term data including well-matched case-control studies will tell if treatment delays/modifications due to Covid 19 have impacted the outcome if children with ALL. Beyond the risk of SARS-CoV-2 infection in patients currently treated for a leukemia vigilance must be maintained regarding the danger of delaying the diagnosis of acute leukemia. Such situations have already been reported with tragic consequences [27,28].

General recommendations
There are still insufficient data to support recommendations applicable to all local cases and situations during the care of children and adolescents and young adults (AYA) with ALL. The most experienced practitioners of the hematology-oncology unit must therefore help to decide, on a case-by-case basis, for which patients should the leukemia treatment be initiated or continued, or identify those in whom a delay is possible, depending on clinical symptoms and tumor biology. For patients in the advanced stage of their disease, the real benefit of the treatment in the context of the risk of COVID-19 must be considered and discussed.

Some general recommendations should be reiterated:
• it is recommended to test for SARS-CoV-2 (preferably by PCR or at least by immunological tests, on nasopharyngeal swab) before starting intensive induction chemotherapy or other intensive phase of treatment, for ALL patients, with or without symptoms, especially in the most affected regions. Due to the unpleasant nature of nasopharyngeal swab tests, they may be difficult to repeat in children. Although salivary tests may be an interesting alternative in the general population, their sensitivity is lower than the one of nasopharyngeal tests. Therefore, we recommend testing preferably with nasopharyngeal swabs in pediatric oncology and hematology wards;
• if patients, before induction therapy, are tested positive for SARS-CoV-2, one should delay systemic treatment if possible (e.g. absence of major hyperleukocytosis). During later phases, if positive, tests should be ideally repeated over time
# Table 1

**Selected COVID-19 studies in children with leukemia**

| Reference                  | Number of patients | Type of study                  | Number of patients with leukemia | COVID-19 complications                                                                 | Use of specific COVID-19 treatment | Outcome in patients with leukemia | Commentaries                                                                 |
|----------------------------|--------------------|--------------------------------|---------------------------------|----------------------------------------------------------------------------------------|-----------------------------------|----------------------------------|-------------------------------------------------------------------------------|
| Millen et al. [20]         | 54                 | Multicenter study, national scale | 24 ALL 4 AML                   | 2 pts with ALL with moderate to severe presentation of COVID-19                        | UK                                | Favorable                        |                                                                                |
| Palomo-colli et al. [67]   | 38                 | Monocenter study               | 21 ALL 3 AML                   | 2 pts requiring invasive ventilation (underlying diagnosis unspecified)                | UK                                | UK                              | 26 pts with delayed oncologic treatment                                        |
| Rouger-Gaudichon et al. [23]| 37                | Multicenter study, national scale | 10 ALL                          | 5 pts requiring ICU transfer (including 2 relapsed ALL, and 1 pt with ALL and H SCT) | REM: 1 pt                         | One death (relapsed ALL treated with chemotherapy)                           | 16 pts with oncologic treatment delayed (median time of 14 days)               |
|                            |                    |                                |                                 |                                                                                        |                                   |                                  |                                                                                |
| Bisogno et al. [19]        | 29                 | Multicenter study, national scale | 14 ALL                          | No complications                                                                      | OHQ: 9 pts, lopinavir/ritonavir: 3 pts | Favorable                        | Prolonged virus shedding in 2 pts (1 AML and 1 ALL)                           |
|                            |                    |                                |                                 |                                                                                        |                                   |                                  | 16 pts with chemotherapy hold (median time of 26 days)                        |
| Ferrari et al. [58]        | 21                 | Multicenter study, regional scale | 10 leukemias                   | No complications in pts with leukemia                                                | UK                                | Favorable                        | Modification of oncologic treatment in 10 pts                                  |
| Gampel et al. [17]         | 19                 | Multicenter study, city scale   | 6 “leukemia or lymphoma”        | 5 pts in ICU including one patient with B-ALL and hyperleukocytosis                  | OHQ + AZITHRO: 3 pts              | Favorable                        | More severity in males in the overall cohort?                                  |
| De Rojas et al. [11]       | 15                 | Multicenter study, city scale   | 8 ALL                           | No complications                                                                      | OHQ: 11 pts, with 3 of them in combination with other drugs (REM, AZITHRO, Toci, steroids) | Favorable                        | 2 pts required oxygen support (no leukemia)                                    |
|                            |                    |                                |                                 |                                                                                        |                                   |                                  | Delayed chemotherapy in 6 pts                                                  |
| Ahmad et al. [59]          | 10                 | Monocenter case series          | Not specified                   | No complications                                                                      | UK                                | Favorable                        | One patient with AML with prolonged shedding of SARS-CoV-2 for 4 weeks        |
| Reference                  | Number of patients | Type of study   | Number of patients with leukemia | COVID-19 complications                                         | Use of specific COVID-19 treatment                        | Outcome in patients with leukemia | Commentaries                                                                 |
|----------------------------|--------------------|-----------------|----------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------|--------------------------------------------------------------------------------|
| Pérez-Martínez et al. [60] | 8                  | Monocenter case series | 2 ALL                            | Macrophage activation syndrome in a T-ALL pt                    | OHQ, REM, tocilizumab and dexamethasone                    | Favorable                         |                                                                                |
| Vicent et al. [15]         | 8                  | Multicenter case series | 3 ALL 1 AML                      | 1 pt with ALL requiring mechanical ventilation                  | OHQ, AZITHRO, REM, Toci, lopinavir/ritonavir, siltuximab and anakinra | One death (ALL & alveolar haemorrhage) |                                                                                |
| Rossof et al. [61]         | 6                  | Monocenter case series | 2 ALL 1 AML                      | One pt with AML required high-flow oxygen                       | UK                                                       | Favorable                         | One pt with T-ALL with prolonged shedding of SARS-CoV-2 for 5 weeks            |
| Flores et al. [62]         | 3                  | Monocenter case series | 3 ALL                            | One pt with recent history of HSCT and under immunosuppressive therapy presented respiratory distress signs, required mechanical ventilation | UK                                                       | One death (patient with history of HSCT) | Two pts on consolidation therapy; favorable outcome                           |
| Stokes et al. [14]         | 2                  | Monocenter case series | 1 AML                            | ICU hospitalization required                                   | OHQ and REM                                               | High BMI                          |                                                                                |
| Phillips et al. [63]       | 1                  | Case report        | 1 ALL                            | Macrophage activation syndrome                                  | No specific treatment                                      | Clinical improvement after the beginning of chemotherapy | Concomitant diagnosis of B-ALL and COVID-19                                   |
| Sieni et al. [13]          | 1                  | Case report        | 1 AML                            | No complication                                                 | OHQ and lopinavir/ritonavir.                              | Favorable                         | 1-year-old girl with high risk AML                                             |
| Orf et al. [64]            | 1                  | Case report        | 1 ALL                            | No complication                                                 | Use of REM. Three drugs induction.                        | Favorable Mild course             | Concomitant diagnosis of standard risk B-ALL and SARS-CoV-2 infection         |
| Balashov et al. [41]       | 1                  | Case report        | 1 JMML                           | Delayed respiratory complications                               | Toci, methylprednisolone, convalescent plasma             | Improvement in 14 days.           | Description of the case of a 9-month-old girl with JMML and HSCT history SARS-CoV-2 still |
### TABLE 1 (Continued)

| Reference         | Type of study | Number of patients with leukemia | COVID-19 complications | Outcomes in patients with leukemia | Use of specific COVID-19 treatments | Comments on treatment | Outcome in patients with leukemia |
|-------------------|---------------|----------------------------------|------------------------|-----------------------------------|-------------------------------------|-----------------------|-----------------------------------|
| N. Bertrand et al. | Case report   | 1                                | ALL                    | Clinical improvement after initial detection | Toci                                | Not recovered. Still in ICU at time of publication | Not recovered. Still in ICU at time of publication |
| Ducassou et al.   | Case report   | 1                                | ALL                    | Clinical improvement after initial detection | Toci                                | Not recovered. Still in ICU at time of publication | Not recovered. Still in ICU at time of publication |
| J. Rouger-Gaudichon et al. | Case report | 1                                | ALL                    | Clinical improvement after initial detection | Toci                                | Not recovered. Still in ICU at time of publication | Not recovered. Still in ICU at time of publication |

until negativity, especially before the beginning of an intensive course;
- if the SARS-CoV-2 test is not available, carefully look for suggestive symptoms (dry cough, high fever, anosmia, rhinorhoea, digestive signs) and/or any notion of contact with a symptomatic individual and consider a chest CT scan;
- carefully isolate any COVID-negative child or adolescent to allow him to securely advance in the treatment (facial mask, social distancing, barrier measures, no contact with individuals suspect of COVID or COVID + for 3 weeks...), in particular for those intended to be allografted;
- visits should be limited to parents and potentially to siblings in hospitalized children, and in the course of hematopoietic stem cell transplantation, with respect of sanitary measures.

### Patients with ALL in first line, included in the CAALL-F01 or ESPHALL 2017 protocols or treated according to the FRALLE/EORTC protocols or INTERFANT 06

**Are you changing your approach to initial induction?**

**General considerations**

Corticosteroids are a key part of induction therapy and, more generally, of ALL treatments. Initial outcomes of the use of corticosteroids in SARS-CoV-2 infection were controversial. Recent data suggested that dexamethasone is effective in severe COVID-19 in immunocompetent patients [29]. The benefit of using corticosteroids in immunocompromised patients with severe COVID-19 is less clear and has not been proven yet. Still, ALL is life-threatening and very probably more than COVID-19 in most situations. Thus, we consider that the risk-benefit ratio calls for regular protocol induction. However, chemotherapy doses and scheduled administration should be weighted with the clinical status and oxygen saturation of the patient, as well as the results of chest computed tomography scan, which should be performed in all patients during this induction phase. In case of significant desaturation (e.g. < 94% of oxygen), signs of respiratory distress and/or more than a 50% lung parenchyma impairment, we recommend pausing chemotherapy. Chemotherapy doses may also be delayed/reduced. Overall, we recommend a multidisciplinary discussion and/or with the protocol coordinators. After completion of chemotherapy, the use of G-CSF in a SARS-CoV-2-positive patient can be discussed to reduce the duration of neutropenia, in the absence of inflammatory signs attributable to COVID-19. The implementation of all or part of treatment on an outpatient basis must be carefully weighed. Indeed, the comings and goings to the ambulatory clinic and blood samplings at home increase the number of contacts at risk. Conversely, return at home could limit contact with caregivers, also possibly being SARS-CoV-2 carriers. A strict policy for family members is obviously to be established.
Note that the risk of needing an intensive care bed during induction therapy of ALL is low (probably <5%). However, in certain regions and/or time frames, the decrease in the number of pediatric ICU beds (transformed into adult resuscitation beds) implies that the pediatric need is being forcefully re-expressed.

**Specific populations**

a. Philadelphia chromosome ALL: some adult hematologists (see ASH adult ALL COVID-19 recommendations) offer treatment with a tyrosine kinase inhibitor with minimal steroid exposure rather than aggressive induction with multidrug therapy for the initial treatment, in the hope of avoiding prolonged hospitalization during the pandemic [30]. However, the recommendation to keep on, including our patients in the EsPhall 2017 protocol with a regular use of imatinib, still seems appropriate to us.

b. Infants under one year of age: the risk of serious forms of COVID-19 in infants has been reported. The test for SARS-CoV-2, possibly repeated, is absolutely necessary here. Again, the recommendation is to follow the current guidelines i.e. to follow the Interrant 06 protocol.

c. Adolescents and young adults: clinicians may consider adolescents and young adults with a particular attention also taking into account the risk factors observed in adults, such as asthma, obesity and diabetes. To insist on compliance with treatment in general but also on adherence to barrier gestures and general sanitary measures, is of paramount importance.

d. Children with Down syndrome: vigilance is essential in these children susceptible to infections in general, even if this susceptibility rarely concerns viral infections. Some reports suggest that patients with Down syndrome have a greater risk of developing severe COVID-19 [31]. Of note, this group benefits from an induction with “only” 3 drugs in the CAALL-F01 protocol, including dexamethasone.

**Are you changing the approach to intensive post-remission therapy (consolidation, delayed intensification)?**

In the absence of data, our recommendation is to follow the protocol, including for corticosteroid therapy. As said in the general recommendations paragraph, each intensive course is to be preceded by a test.

For patients with high-risk ALL, an individualized decision regarding transplantation and its timing is necessary, weighing the risks of transplantation in an epidemic context of COVID-19 against the risk linked to ALL.

**Are you changing your recommendations for maintenance treatment?**

Three problems are mainly to be discussed:

- intensity of maintenance treatment with 6MP/MTX and targets for leukocytosis/neutrophils/lymphocytes: we suggest to follow the usual recommendations of the protocol;
- pulses: monthly pulses (CAALL-F01, B-SR group) or every 10 weeks (CAALL-F01, B-MR group) with vincristine and steroids are to be maintained. In case of symptoms, COVID19 testing the day before, should be performed: if COVID +, then postpone the pulse for about 2 weeks and perform another test before performing the pulse;
- high dose methotrexate cycles in maintenance for T-ALL with high initial leucocyte count (> 100 G/L) and/or CNS3 status: any concern could be discussed with the protocol coordinators. In addition, minimizing hospital visits seems appropriate. Home blood tests are to be preferred and partial use of telemedicine may be considered. However, a physical examination should be performed regularly to avoid any delay in the diagnosis of treatment complications or relapse. Of course, such an attitude is beneficial only if preventive measures are also applied at home.

**Patients with second line or more ALL**

Patients with relapsed ALL may be at greater risk of severe COVID-19 [23]. Test must be performed before starting a chemotherapy block, and postponing chemotherapy in case of positive test should be discussed in accordance with each specific situation and benefits/risks ratio regarding the leukemia.

- First relapse: we propose to include all eligible patients and/or to follow the INTREALL protocol as much as possible. Patients who reach complete remission n°2 should be considered promptly for allogeneic transplantation, as indicated in the protocol, despite the pandemic.
- Second relapse and refractory relapses:
  - Phase I-II trials: most if not all academic or industrial promoters ask now for SARS-CoV2 testing before inclusion. Any positivity is an at least temporary exclusion criterion.
  - CAR-T cells: the indication for treatment with CAR-T cells must be weighed with the center which would perform the procedure: feasibility of performing apheresis (systematic patient testing, problem of using an operating room for apheresis central line placement for example)? Manufacturing feasibility? Feasibility of administration according to the possible rooms in intensive care unit? [32,33]

**What to do if an ALL patient is diagnosed with SARS-CoV-2 infection? What are the interactions between ALL chemotherapy and potential COVID-19 therapy?**

**General recommendations**

1. The diagnosis of SARS-CoV-2 infection during the treatment of ALL should imply to discuss the stopping and/or postponing of all chemotherapies, according to the severity of the ALL, the stage of treatment and the severity of clinical and/or radiological signs. Even if severe forms have been described, most of the experience is currently reassuring [19,20,23].
2. Any "specific" treatment must be discussed with the infectious diseases team. Great efforts have been made to evaluate the efficacy of repurposed drugs against SARS-CoV-2 infection (Tables II and III). Accordingly with the recently published interim analysis of the Solidarity study, there is no clear evidence of efficacy on COVID-19-related mortality of any antiviral agent [34]. Though hydroxychloroquine and lopinavir/ritonavir therapeutic should be abandoned, remdesivir use could eventually be considered. In children, remdesivir may be proposed to positive patients who present potential risk factors of severe COVID-19 and should be given as early as possible in the course of the infection, for 10 days. Above 40 kg of weight, children may receive 200 mg the first day and 100 mg per day the next nine days. Below 40 kg of weight, children may receive 5 mg/kg on the first day and then 2.5 mg/kg once a day until 10 days of treatment [35].

**Which treatments may be considered in case of severe COVID-19?**

As underlined above, any specific anti-COVID-19 treatment should be considered and discussed with the infectious diseases team.

### TABLE II

**Current treatments used or tested in clinical trials**

*Treatments with antiviral potential:*

| Treatment                                      | Notes                                                                 |
|------------------------------------------------|----------------------------------------------------------------------|
| Remdesivir                                     | At best mild efficacy                                                |
|                                                | Possible renal adverse events                                        |
|                                                | Not to be initiated or to be stopped if ALAT ≥ 5 N                   |
|                                                | Low risk of drug interactions (check and update if co-prescription)  |
| Convalescent plasma                            | Unproven efficacy                                                    |
|                                                | No serious adverse events expected                                   |
|                                                | Monitor according to usual transfusion procedures                   |
| Casirivimab and imdevimab monoclonal antibody (Mab) cocktail (REGN-COV2): unproven efficacy | No specific interaction expected                                      |
|                                                | Possible hypersensitivity reaction or infusion-related reaction      |
|                                                | Monitor as for any mAb infusion                                      |

*Treatments acting on the consequences of inflammation:*

| Treatment                                      | Notes                                                                 |
|------------------------------------------------|----------------------------------------------------------------------|
| Corticosteroids: proven efficacy of dexamethasone in immunocompetent adults with a severe form of COVID-19 [29] | Unproven efficacy                                                    |
| Baricitinib: potential efficacy in combination with remdesivir | Potential interaction with methotrexate in theory but no evidence in clinical practice |
| Tocilizumab: controversial efficacy            | No obvious interactions with chemotherapy                             |
| Anakinra: unproven efficacy                   | No obvious interactions with chemotherapy                             |
| Eculizumab: unproven efficacy                 | Randomized protocols in progress in adults                           |


Interestingly, evidence of prolonged viral shedding has been shown in immunosuppressed patients and could lead to discuss a more prolonged administration [36-38]. Among therapies acting on immune system and inflammation, there is no clear evidence that tocilizumab or anakinra are effective. However, dexamethasone use has been proven to be effective [29]. Convalescent plasma use may be safe and beneficial [29,39-41]. Convalescent plasma may especially be useful in immunosuppressed patients [42], but it may not be easily available and, at best, should be considered in a clinical trial setting.

Food and Drug Administration (FDA) has delivered in November 2020 an emergency use authorization for the specific monoclonal antibodies casirivimab and imdevimab against SARS-CoV-2, which may prevent aggravation of COVID-19 in patients who present a high risk of a severe disease [43,44]. An emergency use authorization has also been delivered for a Janus kinase inhibitor, baricitinib, which may be beneficial for patients requiring non-invasive ventilation in association with remdesivir [45]. Interestingly pediatric data are available for baricitinib in the setting of autoinflammatory diseases [46,47]. The French agency (ANSM) has implemented two temporary cohort use authorizations (ATUc) for the casirivimab / imdevimab combination (Roche) and the bamlanivimab / etesevimab combination (Lilly). It is too soon to claim that the monoclonal antibodies and baricitinib are really effective. Their use should ideally be considered in a clinical trial context, which is nevertheless unlikely to occur in the pediatric setting.

**What are the recommendations regarding anticoagulation?**

SARS-CoV-2 infection is associated with hypercoagulability and an increased risk of thrombosis, which participates to disease morbidity and mortality [48]. In children infected with SARS-CoV-2, hemostasis parameters also suggest a state of hypercoagulability, though the thrombotic risk is not well established in this population [49]. D-dimers and fibrinogen should be dosed and disseminated intravascular coagulation should be sought in the case of proven infection, and such dosages should be repeated during the course of COVID-19 [50]. The combination of the prothrombophilic status of the leukemia, the use of asparaginase and the presence of central venous line potentially increase the COVID-19-related thrombotic risk. Therefore, preventive anticoagulation with low molecular weight heparin should be considered. In case of suggestive symptoms, cerebral thrombophlebitis or any other thrombotic complication should be searched for, even in patients treated with preventive anticoagulation.

**Are there biomarkers to predict COVID-19 complications?**

There are currently no specific marker to predict COVID-19 complications. However, COVID-19 may be complicated by inflammation dysregulation and macrophage activation syndrome that may require a higher level of care. Thus, one could recommend to monitor ferritin levels, fibrinogen as well as hepatic enzymes and triglyceride levels, especially for patients who may be at a greater risk. Unfavorable outcomes may also be correlated to high SARS-CoV-2 viremia for which monitoring may be beneficial [51]. Tests may also be repeated until virus clearance, since virus shedding seems to be prolonged in the most immunocompromised patients [37]. Although its prognostic value is less clear in children, lymphopenia is associated with severe SARS-CoV-2 infection in both immunocompetent and immunocompromised adults [52-54]. Lymphopenia is common in children treated with chemotherapy, making difficult to clearly associate it with severe COVID-19. However, closely monitoring lymphocyte counts may be interesting in that context.

### Table III

**Treatments no more recommended**

| Treatment                                      | Recommendation |
|------------------------------------------------|----------------|
| Hydroxychloroquine (OHQ): unproven efficacy. Not recommended | Be cautious about the use of OHQ with other agents prolonging the QTc interval such as azoles, macrolides, levofloxacin, tyrosine kinase inhibitors ++ (TKI) |
| Combination of lopinavir/ritonavir: unproven efficacy. Not recommended | May increase the concentration of methotrexate, monitoring is therefore suggested without empirical dose adjustment interaction with vincristine. Dose reduction to be considered |
| Azithromycin: unproven efficacy. Not recommended | Closely monitor ciclosporin and creatinine blood concentrations Increases QTc |
Who should be vaccinated primarily in the current era?

The recent availability of several vaccines brings a great hope among global population, even if evidence of long-term efficacy and safety are lacking [55–57]. The availability of such vaccines will still be limited in the next months and the priority use will be determined by HTAs (Health Technology Assessments) such as the Haute Autorité de Santé in France. Health care providers aged 50 years or more, or with comorbidities, have been the first professionals in France to receive the vaccine. Those working in our hematology-oncology units should be seen as an example for all health care providers and finally parents and families. Indeed when available, we may recommend to perform the vaccination of parents and siblings of patients who are the most at risk of developing COVID-19 complication (e.g. patients with recent HSCT history, relapsed leukemia under intensive treatment and any patient with significant comorbidity). A recent study suggests that patients with solid tumors may have an effective immune response to SARS-CoV-2, making vaccination in these patients a feasible option [38]. However, the immune response of patients with hematological cancers seems to be impaired, particularly those with B-cell malignancies, which on the one hand may explain their vulnerability and on the other hand argues in favour of vaccination of their relatives [38]. Another issue is the age, since the marketing authorization has been only given according to trial populations age range (lower age limit of 16 and 18 years for the Pfizer and Moderna vaccines respectively). The final issue is that those 2 first vaccines contain polyethylene glycol (PEG), which could be a problem, since children with ALL receive pegylated asparaginase. Vaccination after pegasparagins containing phases or using vaccines without PEG could be reasonable options.

Conclusion

Despite extremely rapid advances obtained in less than one year, our knowledge of SARS-CoV2 and its complications is still incomplete. We presented here an updated version of previous recommendations of the Leukemia committee of the SFCE [1]. We can anticipate that this current version will need an update in the next few months.

Disclosure of interest: the authors declare that they have no competing interest.

Références

[1] Bauchel A, Bertrand Y, Boissel N, Brethon B, Ducassou V, Gandemer V, et al. COVID-19 and acute lymphoblastic leukemias of children and adolescents: first recommendations of the Leukemia committee of the French Society for the Fight against Cancers and Leukemias in children and adolescents (SFCE). Bull Cancer 2020;107(6):629-32.
[2] Bouffet E, Challinor J, Sullivan M, Biondi A, Rodriguez-Galindo C, Pritchard-Jones K. Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences. Pediatr Blood Cancer 2020;67(7):e28327.
[3] Sullivan M, Bouffet E, Rodriguez-Galindo C, Luna-Fineman S, Khan MS, Kearns P, et al. The COVID-19 pandemic: a rapid global response for children with cancer from SIOP-COG, SIOP-E, SIOP-PDCD, IPSO, PROS. CCI and St Jude Global Pediatric Cancer 2020;67(7):e28409.
[4] Liang W, Guan W, Chen K, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21(3):355-7.
[5] Assaad S, Avrillon V, Fournier M-L, Mastromarco B, Russian S, Swialdz A, et al. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-CoV-2 on RT-PCR. Eur J Cancer 2020;135:251-9.
[6] Brat G, Pinheiro LC, Shusterman M, Swed B, Reshetnyak E, Suroka G, et al. COVID-19 severity and outcomes in patients with cancer: a matched cohort study. JCO 2020;38(33):3914-24.
[7] Rüthrich MM, Giessen-Jung C, Borgmann S, Classen AY, Dolfi S, Grüner B, et al. COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry. Ann Hematol 2020;1-11.
[8] Wood M, Neuberg D, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv 2020;4(23):5966-75.
[9] Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V, Brellenghi E, et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer 2020;126(23):5069-76.
[10] Boulad F, Kamboj M, Bouvier N, Maquen A, Kung AL. COVID-19 in children with cancer in New York City. JAMA Oncol 2020;6(9):1459-60.
[11] de Rojas T, Pérez-Martinez A, Cela E, Baragwil M, Galán V, Mata C, et al. COVID-19 infection in children and adolescents with cancer in Madrid. Pediatr Blood Cancer 2020;67(7):e28397.
[12] Terenzianni M, Massimino M, Dossi V, Capanova M, Chiarelli S, Ferrari A, et al. SARS-CoV-2 disease and children under treatment for cancer. Pediatr Blood Cancer 2020;67(9):e28346.
[13] Sieni L, Peguraro F, Casini T, Tondo A, Bertone B, Morlando M, et al. Favorable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukemia and severe treatment-induced immunosuppression. Br J Haematol 2020;189(4):e222-4.
[14] Stokes CL, Patel PA, Sabnis HS, Mitchell SG, Vildirim IB, Pauly MG. Severe COVID-19 disease in two pediatric oncology patients. Pediatr Blood Cancer 2020;67(9):e28432.
[15] Vicent MG, Martinez AP, Castillo MT del, Molina B, Sisins L, Morón-Cazalla G, et al. COVID-19 in pediatric hematopoietic stem cell transplantation: the experience of Spanish group of transplant (GETMON/GETH). Pediatr Blood Cancer 2020;67(9):e28514.
[16] Dantonello TA, Kartal-Kolaer M, Aebi C, Suter-Renicker E, Busch JD, Kubetzko S, et al. SARS-CoV-2 infection during induction chemotherapy in a child with high-risk T cell Acute lymphoblastic Leukemia (T-ALL). J Pediatr Hematol Oncol 2020 [online].
[17] Gampel B, Trouilloud Lucas AG, Brighi L, Garette-Cordiago RD, Lee MT, Levine J, et al. COVID-19 disease in New York City pediatric hematology and oncology patients. Pediatr Blood Cancer 2020;67(9):e28420.
[18] Rouger-Gaudichon J, Gariuzo L, Thébault E, Brethon B, Ferwanth L, Garnant M, et al. Impact of COVID-19 on cancer care: a survey from the French Society of Pediatric Oncology (SFCE). Pediatr Blood Cancer 2020;e28554.
500 Review

[53] Jee J, Foote MB, Lumish M, Stonestrom AJ, Willis B, Narendra V, et al. Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol 2020;38(30):3538-46.

[54] D'uldio N, Yang DD, Madhi F, Levy M, Gaschignard J, Crau I, et al. Factors associated with severe SARS-CoV-2 infection. Pediatrics 2021;147(3). e2020023432.

[55] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397(10269):99-111.

[56] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383(27):2603-15.

[57] Baden LR, El Sahly HM, Esink B, Kato K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384(5):403-16.

[58] Ferrari A, Zecca M, Rizzari C, Porta F, Provenzani M, Marinoni M, et al. Children with cancer in the time of COVID-19: an 8-week report from the six pediatric oncology centers in Lombardia, Italy. Pediatr Blood Cancer 2020;67(8):e28410.

[59] Ahmad N, Ellawel M, Khan WM, Essa MF, Alharbi T, Al-Sudairy R. COVID-19 in pediatric cancer patients: how concerned we should be? Lessons Learned From a Single Center in Middle East. J Pediatr Hematol Oncol 2020. http://dx.doi.org/10.1097/MPH.0000000000002013.

[60] Pérez-Martínez A, Guerra-Garcia P, Melgosa M, Frauca E, Fernández-Cambor C, Remesal C, et al. Clinical outcome of SARS-CoV-2 infection in immunosuppressed children in Spain. Eur J Pediatr 2021;180(3):967-71.

[61] Rossloff J, Patel AB, Muscat E, Kociolek LK, Muller WJ. Benign course of SARS-CoV-2 infection in a series of pediatric oncology patients. Pediatr Blood Cancer 2020;67(9):e28504.

[62] Flores V, Miranda R, Menino L, González C, Serano C, Solano M, et al. SARS-CoV-2 infection in children with febrile neutropenia. Ann Hematol 2020;99(8):1941-2.

[63] Phillips L, Pavisic J, Kaur D, Dorrello NV, Broglie L, Hijja N. Successful management of SARS-CoV-2 acute respiratory distress syndrome and newly diagnosed lymphoblastic leukemia. Blood Adv 2020;4(18):4358-61.

[64] Orf K, Rogosic S, Dexter D, Ancill P, Badde S, Brierley J, et al. Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection. Br J Haematol 2020;190(5):e274-6.

[66] Sun D, Li H, Lu X, Xiao H, Ren J, Zhang FR, Liu ZS. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World J Pediatr 2020;16(3):251-9.

[67] Palomo-Colli MA, Fuentes-Lugo AD, Cobos-Ovando SR, Juárez-Villegas L. COVID-19 in children and adolescents with cancer from a single center in Mexico City. J Pediatr Hematol Oncol 2020. http://dx.doi.org/10.1097/MPH.0000000000002040.